Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials. Expert Rev Vaccines 2006 Oct;5(5):717-32
Date
12/22/2006Pubmed ID
17181444DOI
10.1586/14760584.5.5.717Scopus ID
2-s2.0-33845871185 (requires institutional sign-in at Scopus site) 23 CitationsAbstract
The immune system uses a process known as 'immunosurveillance' to help prevent the outgrowth of tumors. In cancer immunotherapy, a major goal is for immunity against tumor-associated antigens to be generated or strengthened in patients. To achieve this goal, several approaches have been tested, including the use of highly potent antigen-presenting cells called dendritic cells (DCs), which can activate T cells efficiently. Presentation of peptides derived from tumor antigens on the surface of DCs can stimulate strong antitumor immunity. Using recombinant viral vectors encoding tumor-associated antigens, DCs can be engineered efficiently to express sustained levels of tumor-antigen peptides. This review discusses the effectiveness of virally transduced DCs in treating tumors and generating antigen-specific T-cell responses. It covers mouse and nonhuman primate studies, preclinical in vitro human cell experiments and clinical trials.
Author List
Mossoba ME, Medin JAAuthor
Jeffrey A. Medin PhD Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdenoviridaeAnimals
Antigens, Neoplasm
Cancer Vaccines
Cells, Cultured
Clinical Trials as Topic
Dendritic Cells
Dependovirus
Genetic Vectors
Humans
Immunotherapy, Adoptive
Lentivirus
Mice
Neoplasms
Poxviridae
Primates
Retroviridae
Transduction, Genetic